Introduction
Despite significant advances in the treatment of coronary artery disease (CAD), a large number of patients with a history of prior coronary events and multiple coronary interventions are not amenable to further conventional revascularization strategies such as bypass surgery or coronary angioplasty. 1 The concept of therapeutic angiogenesis using genes for growth factors like vascular endothelial growth factor (VEGF) may serve as a novel treatment strategy for such patients who retain underperfused, viable myocardium. 2 Initial clinical studies have been reported with variable results. 3, 4 A large body of evidence from preclinical studies supports the strategy of therapeutic angiogenesis by direct intramyocardial delivery of genes encoding VEGF using naked DNA (pVEGF 165 5 ) or adenoviruses (Ad-VEGF 121 6 ). In addition to the primary therapeutic goal of improving myocardial blood flow, structural changes in the vasculature of the treated myocardial segments (capillary density and collateral development) have also been demonstrated. A systematic assessment of changes in regional myocardial blood flow after gene transfer, however, has not been reported. This is of particular interest for transgenes encoding secreted proteins like VEGF and fibroblast growth factor (FGF) with the potential for inducing biological effects in myocardial areas adjacent to, or even remote from, the treated segments. This spatial 'delivery-efficacy' relation is important to identify the optimal areas for gene delivery and for detecting treatment effects in vivo. The aim of this study was, therefore, to evaluate the effects of localized intramyocardial pVEGF 165 gene transfer on regional myocardial blood flow in a porcine model of chronic myocardial ischaemia.
Results

In vitro validation of VEGF protein expression
Significant VEGF protein expression was documented in vitro 48 h after transfection of Cos7 cells with pVEGF 165 compared to pCAT (13874 vs 2272 ng/mg/ ml, Po0.01, n ¼ 6 per group).
In vivo studies in the porcine model of chronic myocardial ischaemia A total of 28 animals underwent initial ameroid placement. Six animals died during the first 3 weeks after surgery, most likely related to sudden cardiac death. A total of 22 animals underwent intramyocardial gene delivery (11 per group). Of those, two animals (one in each group) died shortly after operation from acute respiratory failure likely the result of anaesthetic problems. One animal in the pCAT group died shortly after induction of pharmacological stress at final studies.
The remaining 20 animals (10 per group) reached final studies 3 weeks after gene transfer and were included in the analysis. Animal weight at baseline (2771 kg) and the animal weight/ameroid size ratio (1171 kg/mm) were identical in both groups. A proximal ameroid position could be achieved in 7/10 of animals receiving pCAT and in 8/10 of those undergoing pVEGF 165 gene transfer.
VEGF 165 gene transcription and protein expression in ischaemic myocardium and serum At 3 weeks after gene delivery, VEGF mRNA could be detected in the target area by RT-PCR in 3/4 animals injected with pVEGF 165 but not in animals injected with pCAT ( Figure 1 , n ¼ 4). VEGF protein expression was detected in the target area, but not in the control area (RV) of animals injected with pVEGF 165 (Po0.05, n ¼ 5-6, Figure 2 ). Significant CAT activity could be detected in the target areas of animals undergoing pCAT gene transfer but not in those receiving pVEGF 165 (4.871.9 Â 10 À4 versus 0.270.03 Â 10 À4 CAT units/mg protein respectively, Po0.01). Serum VEGF protein levels in both groups measured 3 weeks after gene transfer were all below the detection limit of the assay (30 pg/ml).
Haemodynamic evaluation and angiographic results
Measurements of heart rate, mean arterial blood pressure, and left atrial pressure were performed in all study animals 3 weeks after gene transfer under resting and pharmacological stress conditions (Table 1 ). There were no significant differences between groups. At final studies, all ameroids were in place and occlusion rates were statistically not different.
Regional myocardial blood flow after pVEGF 165 gene transfer
At final evaluation, absolute myocardial blood flow was not different between study groups in the target areas, the anterior wall, or the septum. There was, however, a significantly higher myocardial blood flow (MBF) adjacent to the target area in those animals undergoing pVEGF 165 gene transfer under both resting and stress conditions as compared to pCAT controls ( Figure 3 ). When MBF was normalized for each animal to septal flow, there was no effect of pVEGF 165 when administered to the target area (Figure 4a ). However, in the adjacent zone pVEGF 165 produced a significant increase in flow compared to pCAT ( Figure 4b ). As shown in Figure 3 , this resulted from an increase in flow in the adjacent zone, rather than any alteration in septal flow. To analyse further the target area, we compared endocardial and epicardial regions. While animals receiving pVEGF 165 showed a small significant increase in the endocardial/epicardial flow ratio as compared to the pCAT group ( Figure 5 ) at rest, there was no difference during stress. Further, there was no significant improvement in either region during stress. There were no significant differences between the groups.
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Discussion
The effects of direct intramyocardial VEGF gene transfer on regional myocardial blood flow have not been described in detail. Knowledge of the spatial distribution of angiogenic effects is likely to be important in directing gene delivery and detecting treatment effects. The improvement in myocardial blood flow in this study was limited to segments adjacent to the delivery zone. Our results, therefore, demonstrate a spatial 'deliveryefficacy' mismatch.
VEFG and CAT expression in ischaemic myocardium
We confirmed that our plasmid was functional both in vitro and in vivo. As suggested by previous studies, the latter could only be established at the 3 (rather than 6) week time point by tissue, but not serum VEGF protein levels. 5, 7 Further, RT-PCR showed evidence for gene transcription in the target zone. CAT levels were measurable 3 weeks after gene delivery into the ischaemic myocardium, suggesting that this reporter may be useful to address questions such as optimal delivery devices in this model.
Angiographic assessment after pVEGF 165 transfer
We were not able to detect significant changes in the angiographic collateral score as a result of pVEGF 165 gene transfer. The value of coronary collateral assessment as an end point to document treatment effects with therapeutic angiogenesis remains unclear. The Effects of intramyocardial pVEGF165 delivery on regional MBF PW Radke et al diameter of collaterals formed in response to arterial occlusion and/or therapeutic angiogenesis is thought to be o200 mm, 8 which would place them beyond the resolution of conventional angiography. Further, preclinical studies have shown a lack of correlation between collateral grading and myocardial perfusion . 9 Thus, the significance of improvements in collateralization after administration of VEGF protein or VEGF gene therapy suggested by other studies is unclear. 5, 6, 10, 11 Effects of pVEGF 165 gene transfer on regional myocardial blood flow: spatial 'delivery-efficacy' mismatch Using direct intramyocardial injections, pVEGF 165 gene transfer resulted in an improvement in MBF. The most important finding of this study is, however, that these effects were limited to the myocardial segments adjacent to the treated areas, indicating a spatial 'delivery-efficacy' mismatch. A considerable body of evidence suggests that the angiogenic effects of VEGF are enhanced in the presence of ischaemia. This relates to an upregulation in expression of the relevant VEGF receptors. In turn, therefore, the ischaemic target zone in our study should be the focus for the effects of the administered VEGF. However, VEGF is a secreted protein, and has been demonstrated in myocardial sections taken up to 3 cm from the site of injection 5 Capillary proliferation in healing wounds or bordering areas of myocardial infarction originate at the border zones and progress towards the centre. Therefore, one explanation for the observed delivery-efficacy mismatch is that 3 weeks following delivery, the majority of angiogenic activity is occuring at the border zone.
Alternatively, needle injections in the target area may have detrimental effects on VEFG expression and the subsequent angiogenic response. Recent preclinical data, however, suggest that mechanical injury using needle puncture in ischaemic myocardium induces angiogenesis potentially by expression of myocardial iNOS. 12, 13 Finally, VEGF increases both capillary growth and vascular permeability. Regional oedema at the target site as a result of enhanced vascular permeability may have decreased myocardial perfusion in the oedematous area as compared to the adjacent area.
As a consequence, these data may support directing angiogenic genes into myocardial segments at the borders of ischaemic territories. In addition, the observed 'delivery-efficacy' mismatch has implications for detecting treatment effects in vivo. Previous preclinical studies using microsphere techniques may have underestimated the angiogenic efficacy when tissue samples were selectively taken from the treated myocardial segments. 5, 6 Sensitive noninvasive imaging techniques providing regional assessment of blood flow such as positron emission tomography and MRI may overcome this problem in preclinical studies, and are already being evaluated in clinical angiogenesis trials. [14] [15] [16] In conclusion, plasmid VEGF 165 delivery by direct intramyocardial injection to the pig myocardium improves regional perfusion but only in areas adjacent to the site of administration into a region of ischaemia.
Methods Plasmid preparation
The 0.6 kb VEGF cDNA was cloned into an eucaryotic expression vector (pCI, Promega, Southhampton, UK), which contains the CMV immediate-early promoter/ enhancer and a chimeric intron in the 5 0 untranslated region. The chloramphenicol acetyltransferase (CAT) control plasmid was also regulated by the CMV immediate-early promoter/enhancer. After preparation, both plasmids were resuspended in endotoxin/DNasefree sterile water to a final concentration of 1 mg/ml.
In vitro transfection
Semiconfluent Cos7 cells were transfected with pCI-VEGF or a control plasmid, complexed with the cationic lipid DC-Cholesterol:DOPE (1:5 w/w DNA:lipid ratio). Cells were transfected with 5 mg DNA/10 cm 2 well for 6 h, after which the lipid/DNA mixture was replaced with normal growth medium (MEM þ 10% FCS þ 1% ampicillin/streptomycin, Sigma-Aldrich, Dorset, UK). At 48 h after transfection, the medium was removed and frozen at À801C for VEGF quantification. The protein concentration in each well was determined using a modified Folin-Lowry assay 17 and the VEGF concentration was normalized for total protein content.
Porcine model of chronic myocardial ischaemia
Pigs of either sex (age 3 month, 2771 kg, Agrargenossenschaft Bö rde, Germany) were used. All in vivo experiments were carried out at the Institute for Medical Technology Magdeburg, Germany. The study protocol consisted of three study stages: (1) induction of chronic myocardial ischaemia; (2) intramyocardial gene delivery, and (3) final evaluation including regional myocardial blood flow measurements.
All procedures were performed under general anaesthesia. Heart rate, 3-lead ECG, oxygen saturation, and body temperature (rectal) were continuously monitored (Biopac Systems Inc., Santa Barbara, CA, USA) throughout all procedures. Pigs were sedated with a combination of intramuscular (i.m.) ketamine (700-1000 mg), xylazine (100-140 mg), and atropine (0.5 mg), incubated after administration of intravenous (i.v.) propofol (50-60 mg) and mechanically ventilated (Dräger Romulus 800 V, Drägerwerk, Lü beck, Germany). General inhalation anaesthesia was maintained with isoflurane (1.5%) combined with a nitrous oxide/oxygen mixture (ratio of 2:1). Animals received isotonic solution and fentanyl (0.5 mg i.v.). Postoperatively, streptomycin (1250 mg i.m.), penicillin (1000 mg i.m.), and carprofen (150-250 mg i.m.) were administered. After surgery animals were kept in single stalls for 48 h. Thereafter, pigs were housed in groups of four to prevent social deprivation. Experiments were performed according to the Society for Laboratory Animal Science Guidelines, Berlin, Germany and the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). The study protocol was approved by the local Ethics Committee (RP Dessau, Germany).
Induction of chronic myocardial ischaemia
For the purpose of this study, the ameroid constrictor model of myocardial ischaemia was chosen. This model Effects of intramyocardial pVEGF165 delivery on regional MBF PW Radke et al has been widely utilized in preclinical studies of angiogenic therapies. 18 Ameroid placement around the left circumflex coronary artery (LCX) leads to a reduction of myocardial blood flow during excercise-induced or pharmacological stress in the LCX-dependent myocardial regions (left lateral wall). As a result, regional myocardial function decreases and is markedly reduced in the LCX, depending on the left lateral wall as compared to baseline as well as control nonischaemic animals. 18 A left lateral thorocotomy was performed through the fourth or fifth intercostal space. The pericardium was opened and an ameroid constrictor (2.25-2.75 mm inner diameter, Research Instruments, Escondido, USA) was placed around the LCX in the most proximal position possible. The position of the ameroid was described as proximal if placed between the origin of the LCX and the atrial branch, and described as distal if placed distal to the atrial branch. After positioning the constrictor, the pericardium was readapted and closed. The ribs were reopposed and the thorax was closed.
Intramyocardial gene delivery
At 3 weeks after ameroid placement, animals were reassessed and cardiac catheterization undertaken via a standard femoral access. Arterial pressures were continuously monitored and recorded. After administration of a heparin bolus (100 U/kg i.v.), selective angiography of the right and left coronary artery system was performed to assess the degree of ipsi-and contralateral collateralisation of the LCX using the Rentrop score 19 (0, no visible collaterals; 1, faint filling of side branches of the main epicardial vessel without filling the main vessel; 2, partial filling of the main epicardial vessel; 3, complete filling of the main vessel). Recordings of all angiograms were made both on CD and video and analysed off-line.
After coronary angiography, a second thoracotomy was performed in the 5th or 6th intercostal space. The lateral wall of the left ventricle was exposed and the pericardium was reopened. The target territory for gene delivery was defined as a 2.5 Â 2.5 cm 2 area of the left lateral wall 1 cm below the atrioventricular groove and approximately 2 cm downstream of the ameroid constrictor. The transverse boundaries along the course of the LCX were marked with 5.0 prolene in the perivascular fat for subsequent target territory identification at tissue harvesting. A total of 20 intramyocardial injections (1 ml total volume, 50 ml volume per injection) were equally divided into four vertical injection rows of five injections each. The therapeutic gene (pVEGF 165 , 1000 mg) or the reporter gene (pCAT, 1000 mg) were administered into the marked target territory using a 29 G needle. The needle length was fixed at 5 mm using sterile rubber stoppers. With a mean systolic/diastolic thickness of 8-9 mm measured by echocardiography (lateral wall), injections were performed slightly more into the endocardium. After closing the thorax, postoperative care was undertaken as previously described.
Final evaluation and regional myocardial blood flow measurements
At 3 weeks after gene transfer, a final evaluation including coronary angiography and regional myocardial blood flow measurements was performed. Serum samples were taken for measurements of VEGF protein serum levels. Regional myocardial blood flow was assessed under resting and pharmacological stress conditions (dobutamine 8-32 mg/kg/min i.v., target stress heart rate ¼ 2 Â resting heart rate). Two different sets (rest and stress conditions) of stable labelled microspheres (10 7 per injection, 1571 mm diameter, BioPhysics Assay Lab, Worcester, USA) were injected into the left atrium (LA) over a period of 30 s to assess MBF. The correct position of the catheter in the LA was confirmed by pressure recordings and a test injection of contrast dye. Reference arterial blood was withdrawn for 2 min at a constant speed of 5 ml/min from the femoral access, starting 10 s before microsphere injections. Heart rate, systemic arterial, and left atrial pressures were recorded simultaneously before and immediately after the procedure.
After killing, the heart was harvested and a complete transverse mid-myocardial section of the left ventricle was used for systematic evaluation of myocardial blood flow ( Figure 6 ). In addition, tissue samples from the target region and a control region (right ventricle) were snap-frozen and stored at À801C for assessment of pVEGF 165 gene transcription (RT-PCR) and quantitative measurements of CAT and VEGF protein expression.
The principle of myocardial blood flow measurements using the microsphere technique has been described in detail elsewhere. 20 Briefly, tissue and reference blood samples were transferred into appropriate vials (BioPhysics Assay Laboratory, Worcester, USA) immediately after collection and dried before analysis. All vials were analysed using a novel highly sensitive neutron activation technique. 21 The results are reported as disintegrations per minute (dpm) in each sample for each corresponding microsphere label. Absolute regional MBF was calculated from dpm measurements corrected for tissue weight for each individual myocardial segment Effects of intramyocardial pVEGF165 delivery on regional MBF PW Radke et al as follows: MBF (in ml/min/g tissue) ¼ (withdrawal rate (ml/min)/tissue sample weight (g)) Â (dpm (tissue sample)/dpm (blood sample)).
Gene delivery and definition of myocardial segments/ areas were performed in a systematic and reproducible fashion in order to account for the interindividual variability of the coronary anatomy. For the purpose of a systematic analysis of regional myocardial blood flow, a complete mid-papillary section was taken for microsphere analysis using a 15-segment model ( Figure 6 ). For identification of intersegment borders, the prolene markers were used to divide segments 4 and 5/6 as well as segments 7/8 and 9. The LAD was then used as an anatomic landmark to separate segments 1 and 15. Finally, the insertion of the right ventricle was used to separate segments 11 and 12. Consequently, segments were clustered to define myocardial areas.
The following four myocardial areas of the left ventricle were specified and calculations were performed for each area separately: (1) target area (TA, segments 5-8), (2) adjacent area (ADJ, segments 4 and 9), (3) anterior wall (ANT, segments 1-2), (4) septum (SEPT, segments 12-15). The target area was further divided into an endocardial section (ENDO, segments 6 and 8) and an epicardial section (EPI, segments 5 and 7) and the flow ratio between ENDO and EPI was calculated (ENDO/EPI). The degree of myocardial ischaemia in the target and adjacent areas was expressed as follow: Ischaemia TA ¼ (MBF TA/MBF SEPT), and Ischaemia ADJ ¼ (MBF ADJ/MBF SEPT). Segments 3 (anterolateral), and 10/11 (inferior) were classified as intermediate segments and were not included into the analysis. Analysis of the tissue and blood vials using neutron activation and calculations of myocardial blood flow were performed in a blinded fashion.
RNA preparation and RT-PCR
Preparation of mRNA from injected myocardium was performed using the RNeasy Midi Kit and Oligotex mRNA (QIAGEN Ltd., Crawley, UK) according to the manufacturer's recommendations. Preparation of cDNA was performed using the Omniscript RT-PCR kit (QIA-GEN Ltd., Crawley, UK) and PCR was carried out (VEGF forward: 5 0 AGT CTC GAA CTT AAG CTG3 0 , VEGF reverse: 5 0 GCC TTG GTG AGG TTT GAT3 0 , 941C for 5 min, 30 cycles of 941C for 30 s, 581C for 45 s and 721C for 1 min, followed by 721C for 10 min) using a High Fidelity PCR system (Roche Diagnostics Ltd., Lewes, UK). The expected product size from VEGF RNA amplification was 490 bp and from plasmid DNA amplification was 620 bp, due to the presence of a chimeric intron in the 5 0 untranslated region of the expression plasmid. Control reactions without reverse transcriptase (ÀRT) were carried out for all samples. Analysis was performed in a blinded fashion.
VEGF and CAT detection in myocardial tissue and serum
Myocardial tissue (0.15-0.3 g) from the target area and control areas (right ventricle) was homogenized in 2000 ml HEPES buffer (20 mM HEPES, pH 7.4, 1.5 mM EDTA). Following three freeze/thaw cycles, the tissue lysates were spun for 10 min at 13 000 rpm and the supernatant frozen at À801C. The protein concentration in tissue homogenates was determined using a modified Folin-Lowry assay. 17 For VEGF serum measurements, total blood was spun at 4000 rpm for 10 min and the serum was removed and frozen at À801C. VEGF was measured in tissue lysates and serum using a human VEGF ELISA (R&D Systems, Abingdon, UK) according to the manufacturer's protocol. CAT enzymatic activity was assessed as described before. 22 All analyses were performed in a blinded fashion.
Statistical analysis
All data are expressed as mean7s.e.m. for convenience. Levels of reporter and therapeutic protein expression were compared using the Mann-Whitney U-test. Baseline characteristics of the study animals in the two treatment groups were compared using the MannWhitney U-test for continuous variables and the Fisher's exact test for categorical variables. Myocardial blood flow in the six specified myocardial areas and the level of ischaemia for the target and adjacent areas were assessed for each group and compared between groups using the Mann-Whitney U-statistical test. The null hypothesis was rejected at Po0.05.
